Humacyte Inc. announced that long-term safety, efficacy and durability data for its Symvess® acellular tissue engineered vessel in extremity arterial trauma repair were presented at the Vascular & Endovascular Surgery Society (VESS) Annual Winter Meeting 2026. The presentation reported outcomes from the V005 Phase 2/3 trial in 54 patients followed for up to 36 months, including a 92.9% infection-free rate from months 3–36 with no infections after day 37, limb salvage rates of 87.3% at 12 months and 82.5% at 24 months, and ultrasound findings showing average mid-graft diameter remained near a 6 mm baseline with no reported spontaneous ruptures or unprovoked structural failures through 36 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602180800PRIMZONEFULLFEED9656209) on February 18, 2026, and is solely responsible for the information contained therein.